Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor

Bibliography

• Kessler RC, Berglund P, Demler O, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
   PubMed Web of Science ®Google Scholar
• Andrews G. Should depression be managed as a chronic disease? BMJ 2001;322:419-21
   PubMed Web of Science ®Google Scholar
• Vuorilehto MS, Melartin TK, Isometsa ET. Course and outcome of depressive disorders in primary care: a prospective 18-month study. Psychol Med 2009;39:1697-707
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-304
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Hollander E, Nutt D, Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008;69:246-58
   PubMed Web of Science ®Google Scholar
• Rausch JL, Johnson ME, Fei YJ, Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002;51:723-32
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89-295
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Gibson BB, Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull 2008;31:231-4
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Serretti A, ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:398-404
   PubMed Web of Science ®Google Scholar
• Pristiq [package insert]. Wyeth Pharmaceuticals, Inc., Philadelphia, PA; 2009
   Google Scholar
• Pfizer Pipeline—our medicine in development. Pfizer Web site. 2010. Available from: http://www.pfizer.com/research/pipeline/pipeline.jsp. [Accessed 1 October 2010]
   Google Scholar
• Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics 2005;46:464-94
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Nichols AI, Paul J, Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008;14:368-78
   PubMed Web of Science ®Google Scholar
• Preskorn S, Patroneva A, Silman H, Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009;29:39-43
   PubMed Web of Science ®Google Scholar
• Otton SV, Ball SE, Cheung SW, Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-56
   PubMed Web of Science ®Google Scholar
• Fogelman SM, Schmider J, Venkatakrishnan K, O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999;20:480-90
   PubMed Web of Science ®Google Scholar
• Howell SR, Husbands GE, Scatina JA, Sisenwine SF. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993;23:349-59
   PubMed Web of Science ®Google Scholar
• Lantz RJ, Gillespie TA, Rash TJ, Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003;31:1142-50
   PubMed Web of Science ®Google Scholar
• Cymbalta [package insert]. Eli Lilly & Co., Indianapolis, IN; 2004
   Google Scholar
• Lobo ED, Bergstrom RF, Reddy S, In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008;47:191-202
   PubMed Web of Science ®Google Scholar
• Effexor XR [package insert]. Wyeth Pharmaceuticals, Philadelphia, PA; 2003
   Google Scholar
• Lobello KW, Preskorn SH, Guico-Pabia CJ, Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010. [Epub ahead of print]
   Google Scholar
• Paxil CR [package insert]. GlaxoSmithKline, Research Triangle Park, NC; 2004
   Google Scholar
• Patroneva A, Connolly SM, Fatato P, An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008;36:2484-91
   PubMed Web of Science ®Google Scholar
• Nichols AI, Fatato P, Shenouda M, The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009;49:219-28
   PubMed Web of Science ®Google Scholar
• Oganesian A, Shilling AD, Young-Sciame R, Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull 2009;42:47-63
   PubMed Web of Science ®Google Scholar
• US Department of Health & Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry – Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling (2006). Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. [Accessed 16 November 2009]
   Google Scholar
• Weiss J, Dormann SM, Martin-Facklam M, Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197-204
   PubMed Web of Science ®Google Scholar
• Clarke G, O'Mahony SM, Cryan JF, Dinan TG. Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter? Hum Psychopharmacol 2009;24:217-23
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U, Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK, Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
   PubMed Web of Science ®Google Scholar
• Thase ME, Kornstein SG, Germain JM, An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Rosas G, An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Shelton RC. Serotonin norepinephrine reuptake inhibitors: similarities and differences. Prim Psychiatry 2009;16:25-35
   Google Scholar
• Lieberman DZ, Montgomery SA, Tourian KA, A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008;23:188-97
   PubMed Web of Science ®Google Scholar
• Tourian KA, Padmanabhan SK, Groark J, Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31(Pt 1):1405-23
   PubMedGoogle Scholar
• Soares CN, Thase ME, Clayton A, Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010;17:700-11
   PubMed Web of Science ®Google Scholar
• Paykel ES, Weissman MM. Social adjustment and depression. A longitudinal study. Arch Gen Psychiatry 1973;28:659-63
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Montgomery SA, Keller MB, Social functioning in depression: a review. J Clin Psychiatry 2000;61:268-75
   PubMed Web of Science ®Google Scholar
• Miller IW, Keitner GI, Schatzberg AF, The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-19
   PubMed Web of Science ®Google Scholar
• Solomon DA, Leon AC, Endicott J, Psychosocial impairment and recurrence of major depression. Compr Psychiatry 2004;45:423-30
   PubMed Web of Science ®Google Scholar
• Sheehan DV. Sheehan disability scale. In: Rush AJ, Pincus HA, First MB, editors, Handbook of psychiatric measures. American Psychiatric Association, Washington, DC; 2000. p. 113-15
   Google Scholar
• Soares CN, Kornstein SG, Thase ME, Assessng the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry 2009;70:1365-71
   PubMed Web of Science ®Google Scholar
• Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 2008;23:70-83
   PubMed Web of Science ®Google Scholar
• Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-59S
   PubMed Web of Science ®Google Scholar
• Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8
   PubMed Web of Science ®Google Scholar
• Hudson JI, Wohlreich MM, Kajdasz DK, Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327-41
   PubMed Web of Science ®Google Scholar
• Thase ME, Tran PV, Wiltse C, Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005;25:132-40
   PubMed Web of Science ®Google Scholar
• Chen SY, Hansen RA, Farley JF, Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment. Psychiatr Serv 2010;61:81-5
   PubMed Web of Science ®Google Scholar
• Silkey B, Preskorn SH, Golbeck A, Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 2005;11:16-26
   PubMedGoogle Scholar
• Bech P, Gram LF, Dein E, Quantitative rating of depressive states. Acta Psychiatr Scand 1975;51:161-70
   PubMed Web of Science ®Google Scholar